Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus VERARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus VERARD.
ADALAT CC vs VERARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Verard (vericiguat) is a soluble guanylate cyclase (sGC) stimulator. It sensitizes sGC to endogenous nitric oxide (NO) and directly stimulates sGC independently of NO, thereby increasing cyclic guanosine monophosphate (cGMP) production, leading to vasodilation and anti-remodeling effects in the heart and vasculature.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
400 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life 12-15 hours; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal excretion (70% unchanged, 20% as inactive metabolites), biliary/fecal (10%).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker